Bloomberg reports that Merck plans to cut 8,500 workers in addition to the 7,500 jobs already announced amid overhaul in R&D department. The latest has got new chief - Roger Perlmutter, who replaced ineffective Peter Kim under which experimental drugs in cardiovascular, surgery, and osteoporosis had development setbacks. New primary care drugs developed before Perlmutter took the office either haven’t been approved, or are likely to face limited sales. Do you think that new chief will be successful? http://www.bloomberg.com/news/2013-10-01/merck-top-scientist-plans-major-changes-for-drug-research.html